Clarity For Celgene On Revlimid, A Backbone Of MM Treatment
Executive Summary
Celgene reached a patent settlement with generic rival Natco that will allow entry of generic lenalidomide in March 2022, but only a limited quantity initially.
You may also be interested in...
Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.